The 2019 novel coronavirus (officially known as severe acute respiratory syndrome coronavirus 2, SARS-CoV2)was first found in Wuhan, China. On February 11, 2020, the World Health Organization (WHO) has declared theoutbreak of the disease caused by SARS-CoV2, named coronavirus disease 2019 (COVID-19), as an emergencyof international concern. Based on the current epidemiological surveys, some COVID-19 patients with severeinfection gradually develop impairment of the respiratory system, acute kidney injury (AKI), multiple organfailure, and ultimately, death. Currently, there is no established pharmacotherapy available for COVID-19. Asseen in influenza, immune damage mediated by excessive production of inflammatory mediators contributesto high incidence of complications and poor prognosis. Thus, removal or blocking the overproduction of thesemediators potentially aids in reducing the deleterious cytokine storm and improving critically ill patients’ out-comes. Based on previous experience of blood purification to treat cytokine storm syndrome (CSS) in severeacute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), here we aimed to review thecurrent literature on extracorporeal hemoperfusion as a potential therapeutic option for CSS-associated condi-tions, with a focus on severe COVID-19.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.